Paolo Tarantino: We need Biomarkers to Tailor Treatment with T-DXd
Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute and Harvard Medical School, reshared a post by Dana-Farber’s Breast Oncology Center, on X:
“Dr. Isaacs made it clear in her DB09 discussion: we need biomarkers to tailor treatment with T-DXd!
At Dana-Farber’s Breast Oncology Center, we’re committed to develop them.
With the help of terrific partners, we tested HER2DX & RPPA in a pilot of 40 pts.
Intriguing results, working on validation.”
Quoting Dana-Farber’s Breast Oncology Center‘s post:
“Metastatic Breast Cancer Poster Session:
Quantitative pre-treatment assessment of trastuzumab deruxtecan (TDXd) antibody target (HER2) and payload target (topoisomerase 1, Topo1) to predict outcomes in Metastatic Breast Cancer (MBC).
Abstract 1032 | Poster Bd 11 | Jun 2, 9-12 PM CDT | Hall A.”
More posts featuring Paolo Tarantino.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023